TGTX
TG Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -23.1% ·
share flow -30.0% ·
net new positions -20.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 55.52K | $2.21M | n/a | −1 |
| Q2 2026 | 115 | +11 | 84.48M | $4.64B | +13 | −4 |
| Q1 2026 | 109 | 0 | 78.24M | $2.60B | +7 | −7 |
| Q4 2025 | 108 | 0 | 85.68M | $2.55B | n/a | n/a |
| Q3 2025 | 18 | +1 | 56.55M | $2.04B | +1 | −1 |
| Q2 2025 | 15 | 0 | 56.34M | $2.03B | +1 | −1 |
| Q1 2025 | 12 | +2 | 14.38M | $567.04M | +2 | n/a |
| Q4 2024 | 10 | -1 | 14.56M | $438.37M | n/a | −1 |
| Q3 2024 | 10 | -3 | 5.57M | $130.22M | n/a | −3 |
| Q2 2024 | 13 | n/a | 11.93M | $212.32M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 3.21M | 0.0% | $74.98M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 2 | Two Sigma Investments ✦ | 1.06M | -21.9% | $24.86M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 3 | Norges Bank ✦ (passive) | 437.46K | -26.8% | $10.23M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 394.78K | +64.5% | $9.23M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 5 | Citadel Advisors ✦ | 125.13K | -93.3% | $2.93M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Gotham Asset Management ✦ | 115.28K | +57.3% | $2.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 81.50K | -7.3% | $1.91M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 73.32K | +12.7% | $1.71M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 9 | AQR Capital Management ✦ | 59.44K | +56.3% | $1.39M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 10 | Millennium Management ✦ | 11.79K | -99.2% | $275,862 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $36.50M | was 0.1% |
| Point72 Asset Management | $10.42M | was 0.0% |
| Renaissance Technologies | $5.50M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 359 holders, 105.22M shares, $3.44B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 5.00K sh · $274,800
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology